Skip to main content

Table 2 Baseline characteristics of the individual case safety reports concerning immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis

From: Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports

Characteristic Patients No. (%) (n = 38)
Age
 Reported 33 (87)
  Median [IQR], years 63 [45–72]
 Not reported 5 (13)
Sex
 Male 29 (76)
 Female 9 (24)
Cancer type
 Melanoma 21 (55)
 Lung cancer 5 (13)
 Bladder cancer 3 (8)
 Renal cell carcinoma 2 (5)
 Hodgkin disease 1 (3)
 Transitional cell carcinoma 1 (3)
 Adenocarcinoma gastric 1 (3)
 Thymoma 1 (3)
 T cell lymphoblastic leukemia acute 1 (3)
 Not reported 2 (5)
Co-suspected drugs
 Reported 4 (10)
  Antineoplastic agents 2 (5)
  Antibacterial agents 2 (5)
 Not reported 34 (90)
Drugs
 Anti-CTLA-4 (ipilimumab) monotherapy 7 (18)
 Anti-PD-1 monotherapy
  nivolumab 14 (37)
  pembrolizumab 7 (18)
 Anti-PD-L1 monotherapy
  Atezolizumab 1 (3)
 ipilimumab and nivolumab combination therapy 5 (13)
 nivolumab and ipilimumab sequential therapy 3 (8)
 pembrolizumab and ipilimumab sequential therapy 1 (3)
Reporting
 2014 1 (3)
 2015 3 (8)
 2016 6 (16)
 2017 10 (26)
 2018 18 (47)
  1. Abbreviations: IQR interquartile range, CTLA-4 Cytotoxic T-Lymphocyte Antigen 4, PD-1 Programmed cell Death protein 1, PD-L1 Programmed cell Death-Ligand 1